Literature DB >> 7671965

Galactitol in galactosemia.

C Jakobs1, S Schweitzer, B Dorland.   

Abstract

Urinary galactose and galactitol excretion in controls is age-dependent with the highest concentrations at a younger age. Untreated patients with classical galactosemia excreted highly elevated amounts of galactitol (8000-69,000 mmol/mol creatinine; controls 3-81) which did not correlate with galactose excretion. After treatment, galactose excretion returned to normal in all patients whereas galactitol excretion (45-900 mmol/mol creatinine) remained above the age-matched control range. The excretion of galactitol (96-170 mmol/mol creatinine) in untreated compound heterozygotes was much lower although still above the age-matched control levels, and it returned to normal after treatment. In untreated classical galactosemia patients the galactitol in plasma (120-500 mumol/l) was markedly elevated (controls 0.08-0.86 mumol/l); under treatment, the galactitol concentrations (4.7-20 mumol/l) remained above the control range in all. There was no correlation with age nor with galactose-1-phosphate and UDP-galactose levels. Two untreated compound heterozygotes had elevated plasma galactitol (6.0 and 63 mumol/l) which, when treated, returned to normal.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7671965     DOI: 10.1007/bf02143804

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  13 in total

1.  Long-term prognosis in galactosaemia: results of a survey of 350 cases.

Authors:  D D Waggoner; N R Buist; G N Donnell
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

Review 2.  Nucleotide sugars: determination of cellular levels and discrepancies in results.

Authors:  Y S Shin
Journal:  Eur J Pediatr       Date:  1995       Impact factor: 3.183

3.  Determination of sorbitol and galactitol at the nanogram level in biological samples by high-performance liquid chromatography.

Authors:  J M Dethy; B Callaert-Deveen; M Janssens; A Lenaers
Journal:  Anal Biochem       Date:  1984-11-15       Impact factor: 3.365

4.  Galactitol in the tissues of a galactosemic child.

Authors:  R Quan-Ma; H J Wells; W W Wells; F E Sherman; T J Egan
Journal:  Am J Dis Child       Date:  1966-11

Review 5.  Galactose and cataract.

Authors:  D Stambolian
Journal:  Surv Ophthalmol       Date:  1988 Mar-Apr       Impact factor: 6.048

6.  The effect of dietary fruits and vegetables on urinary galactitol excretion in galactose-1-phosphate uridyltransferase deficiency.

Authors:  G T Berry; M Palmieri; K C Gross; P B Acosta; J A Henstenburg; A Mazur; R Reynolds; S Segal
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

7.  Stable isotope dilution analysis of galactitol in amniotic fluid: an accurate approach to the prenatal diagnosis of galactosemia.

Authors:  C Jakobs; T G Warner; L Sweetman; W L Nyhan
Journal:  Pediatr Res       Date:  1984-08       Impact factor: 3.756

8.  Capillary gas chromatographic profiling of urinary, plasma and erythrocyte sugars and polyols as their trimethylsilyl derivatives, preceded by a simple and rapid prepurification method.

Authors:  G Jansen; F A Muskiet; H Schierbeek; R Berger; W van der Slik
Journal:  Clin Chim Acta       Date:  1986-06-30       Impact factor: 3.786

Review 9.  Galactose-1-phosphate in the pathophysiology of galactosemia.

Authors:  R Gitzelmann
Journal:  Eur J Pediatr       Date:  1995       Impact factor: 3.183

Review 10.  Effects of galactosemia in utero.

Authors:  J B Holton
Journal:  Eur J Pediatr       Date:  1995       Impact factor: 3.183

View more
  10 in total

1.  Komrower Lecture. Galactosaemia today: the enigma and the challenge.

Authors:  S Segal
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

Review 2.  Classical galactosaemia revisited.

Authors:  Annet M Bosch
Journal:  J Inherit Metab Dis       Date:  2006-07-11       Impact factor: 4.982

3.  Oxidation of galactose by galactose-1-phosphate uridyltransferase-deficient lymphoblasts.

Authors:  C Yager; J Gibson; B States; L J Elsas; S Segal
Journal:  J Inherit Metab Dis       Date:  2001-08       Impact factor: 4.982

4.  Structure of 2-oxo-3-deoxygalactonate kinase from Klebsiella pneumoniae.

Authors:  Karolina Michalska; Marianne E Cuff; Christine Tesar; Brian Feldmann; Andrzej Joachimiak
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-07-12

5.  Transaldolase deficiency: liver cirrhosis associated with a new inborn error in the pentose phosphate pathway.

Authors:  N M Verhoeven; J H Huck; B Roos; E A Struys; G S Salomons; A C Douwes; M S van der Knaap; C Jakobs
Journal:  Am J Hum Genet       Date:  2001-03-27       Impact factor: 11.025

6.  Renal excretion of galactose and galactitol in patients with classical galactosaemia, obligate heterozygous parents and healthy subjects.

Authors:  P Schadewaldt; S Killius; L Kamalanathan; H W Hammen; K Strassburger; U Wendel
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

Review 7.  Galactosemia unsolved.

Authors:  S Segal
Journal:  Eur J Pediatr       Date:  1995       Impact factor: 3.183

8.  Compound heterozygosity with a novel S222N GALT mutation leads to atypical galactosemia with loss of GALT activity in erythrocytes but little evidence of clinical disease.

Authors:  Benjamin Cocanougher; Umut Aypar; Amber McDonald; Linda Hasadsri; Michael J Bennett; W Edward Highsmith; Kristin D'Aco
Journal:  Mol Genet Metab Rep       Date:  2015-01-21

Review 9.  Sweet and sour: an update on classic galactosemia.

Authors:  Ana I Coelho; M Estela Rubio-Gozalbo; João B Vicente; Isabel Rivera
Journal:  J Inherit Metab Dis       Date:  2017-03-09       Impact factor: 4.982

10.  Biochemical and computational analyses of two phenotypically related GALT mutations (S222N and S135L) that lead to atypical galactosemia.

Authors:  Benjamin Cocanougher; Umut Aypar; Amber McDonald; Linda Hasadsri; Michael J Bennett; W Edward Highsmith; Kristin D׳Aco
Journal:  Data Brief       Date:  2015-02-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.